Northside Hospital Cancer Institute is committed to providing high-quality prostate cancer treatment options. The health system now offers a breakthrough treatment for men with one of the advanced forms of the disease.
PLUVICTO® is an FDA-approved radioactive therapy drug used to treat men with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC).
Northside is one of the few cancer centers in Georgia to offer treatment with PLUVICTO. It is available at Northside’s campuses in Atlanta, Cherokee, Forsyth and Gwinnett.
Prostate cancer is the most common cancer among men, behind skin cancer. One in every eight men will be diagnosed with the disease during his lifetime and it is the second leading cause of cancer death in men.
Northside Hospital Cancer Institute is among the top prostate and urologic cancer programs in Georgia.
“mCRPC is a type of prostate cancer that has metastasized, or spread, beyond the prostate to other parts of the body and is no longer responding to hormone treatment,” said Dr. Crain Garrot, a Georgia Cancer Specialists and Northside Hospital Cancer Institute physician.
Administered through an IV, PLUVICTO locates cancer in the body and delivers a microscopic amount of radiation directly to the cancer cells, killing or damaging them with minimal harm to surrounding healthy tissue. The full treatment is given as six separate infusions, six weeks apart.
“Our team is committed to providing all patients with high-quality, evidence-based prostate cancer treatment options and to making access to cancer care as convenient as possible,” added Dr. Garrot. “PLUVICTO may be life-extending for patients with metastatic prostate cancer.”
To qualify for PLUVICTO, patients must have been treated with androgen receptor (AR) pathway inhibition and at least one taxane-based chemotherapy treatment.
Providers can call 404-851-8941 to learn more or to schedule a patient for treatment.
